Reviva Pharmaceuticals Holdings, Inc. – NASDAQ:RVPH

Founder-led company

Reviva Pharmaceuticals Holdings stock price today

$0.529
-1.27
-70.6%
Financial Health
0
1
2
3
4
5
6
7
8
9

Reviva Pharmaceuticals Holdings stock price monthly change

+45.16%
month

Reviva Pharmaceuticals Holdings stock price quarterly change

+45.16%
quarter

Reviva Pharmaceuticals Holdings stock price yearly change

-64.98%
year

Reviva Pharmaceuticals Holdings key metrics

Market Cap
58.45M
Enterprise value
N/A
P/E
-3.58
EV/Sales
N/A
EV/EBITDA
N/A
Price/Sales
N/A
Price/Book
7.14
PEG ratio
0.04
EPS
-1.71
Revenue
N/A
EBITDA
-36.49M
Income
-37.65M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Reviva Pharmaceuticals Holdings stock price history

Reviva Pharmaceuticals Holdings stock forecast

Reviva Pharmaceuticals Holdings financial statements

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH): Profit margin
Dec 2022 0 -8.11M
Mar 2023 0 -6.60M
Jun 2023 0 -12.44M
Sep 2023 0 -10.49M
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH): Analyst Estimates
Jun 2023 0 -12.44M
Sep 2023 0 -10.49M
Sep 2025 0 -5.84M
Dec 2025 0 -5.60M
  • Analysts Price target

  • Financials & Ratios estimates

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH): Debt to assets
Dec 2022 18923675 6.60M 34.92%
Mar 2023 12901523 7.11M 55.16%
Jun 2023 11842022 10.22M 86.31%
Sep 2023 5387041 13.90M 258.15%
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH): Cash Flow
Sep 2022 -4.00M 0 7.77M
Dec 2022 -4.69M 0 18.56K
Mar 2023 -7.95M 0 687.09K
Jun 2023 -5.31M 0 5.21M

Reviva Pharmaceuticals Holdings alternative data

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH): Employee count
Aug 2023 10
Sep 2023 10
Oct 2023 10
Nov 2023 10
Dec 2023 10
Jan 2024 10
Feb 2024 10
Mar 2024 10
Apr 2024 10
May 2024 15
Jun 2024 15
Jul 2024 15

Reviva Pharmaceuticals Holdings other data

0.94% -7.87%
of RVPH is owned by hedge funds
139.09K -1.16M
shares is hold by hedge funds

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH): Insider trades (number of shares)
Period Buy Sel
Jun 2022 50000 0
Sep 2022 50000 0
Nov 2022 3000 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
PATEL PURAV director
Common Stock, par value $0.0001 per share 3,000 $4.69 $14,070
Purchase
NARAYAN PRABHU officer: Chief Financial Officer
Common Stock, par value $0.0001 per share 50,000 $1.66 $83,000
Purchase
NARAYAN PRABHU officer: Chief Financial Officer
Common Stock, par value $0.0001 per share 50,000 $1.21 $60,650
Purchase
VEDANTA PARTNERS, LLC
Common Stock 1,330,000 $3.94 $5,237,540
Sale
GLAZER CAPITAL, LLC
Ordinary Shares, no par value 367,000 $10.88 $3,992,960
Sale
HUDSON BAY CAPITAL MANAGEMENT LP
Ordinary Shares, no par value 50,000 N/A N/A
Sale
GLAZER CAPITAL, LLC
Ordinary Shares, no par value 261 $11 $2,871
Sale
GLAZER CAPITAL, LLC
Ordinary Shares, no par value 5,362 $11 $58,982
Sale
GLAZER CAPITAL, LLC
Ordinary Shares, no par value 5,969 $10.9 $65,062
Sale
GLAZER CAPITAL, LLC
Ordinary Shares, no par value 7,103 $10.9 $77,423
Insider Compensation
Dr. Laxminarayan Bhat Ph.D. (1965) Founder, Chief Executive Officer, Pres & Director
$247,950
Monday, 16 December 2024
globenewswire.com
Wednesday, 11 December 2024
seekingalpha.com
Thursday, 14 November 2024
globenewswire.com
Wednesday, 6 November 2024
globenewswire.com
Thursday, 31 October 2024
globenewswire.com
Tuesday, 8 October 2024
globenewswire.com
Wednesday, 2 October 2024
globenewswire.com
Wednesday, 21 August 2024
globenewswire.com
Tuesday, 9 July 2024
globenewswire.com
Saturday, 1 June 2024
accesswire.com
Thursday, 30 May 2024
prnewswire.com
Wednesday, 29 May 2024
globenewswire.com
Tuesday, 28 May 2024
globenewswire.com
Thursday, 23 May 2024
prnewswire.com
Tuesday, 21 May 2024
globenewswire.com
Thursday, 16 May 2024
prnewswire.com
Wednesday, 15 May 2024
globenewswire.com
Tuesday, 14 May 2024
globenewswire.com
Monday, 13 May 2024
GlobeNewsWire
Thursday, 28 March 2024
GlobeNewsWire
Tuesday, 26 March 2024
GlobeNewsWire
Monday, 11 March 2024
GlobeNewsWire
Tuesday, 20 February 2024
GlobeNewsWire
Tuesday, 23 January 2024
InvestorPlace
Wednesday, 10 January 2024
Accesswire
Thursday, 30 November 2023
GlobeNewsWire
Thursday, 2 November 2023
Seeking Alpha
Monday, 30 October 2023
Reuters
Wednesday, 27 September 2023
Seeking Alpha
Thursday, 7 September 2023
GlobeNewsWire
  • What's the price of Reviva Pharmaceuticals Holdings stock today?

    One share of Reviva Pharmaceuticals Holdings stock can currently be purchased for approximately $0.53.

  • When is Reviva Pharmaceuticals Holdings's next earnings date?

    Unfortunately, Reviva Pharmaceuticals Holdings's (RVPH) next earnings date is currently unknown.

  • Does Reviva Pharmaceuticals Holdings pay dividends?

    No, Reviva Pharmaceuticals Holdings does not pay dividends.

  • How much money does Reviva Pharmaceuticals Holdings make?

    Reviva Pharmaceuticals Holdings has a market capitalization of 58.45M.

  • What is Reviva Pharmaceuticals Holdings's stock symbol?

    Reviva Pharmaceuticals Holdings, Inc. is traded on the NASDAQ under the ticker symbol "RVPH".

  • What is Reviva Pharmaceuticals Holdings's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Reviva Pharmaceuticals Holdings?

    Shares of Reviva Pharmaceuticals Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Reviva Pharmaceuticals Holdings's key executives?

    Reviva Pharmaceuticals Holdings's management team includes the following people:

    • Dr. Laxminarayan Bhat Ph.D. Founder, Chief Executive Officer, Pres & Director(age: 60, pay: $247,950)
  • Is Reviva Pharmaceuticals Holdings founder-led company?

    Yes, Reviva Pharmaceuticals Holdings is a company led by its founder Dr. Laxminarayan Bhat Ph.D..

  • How many employees does Reviva Pharmaceuticals Holdings have?

    As Jul 2024, Reviva Pharmaceuticals Holdings employs 15 workers, which is 50% more then previous quarter.

  • When Reviva Pharmaceuticals Holdings went public?

    Reviva Pharmaceuticals Holdings, Inc. is publicly traded company for more then 6 years since IPO on 18 Oct 2018.

  • What is Reviva Pharmaceuticals Holdings's official website?

    The official website for Reviva Pharmaceuticals Holdings is revivapharma.com.

  • Where are Reviva Pharmaceuticals Holdings's headquarters?

    Reviva Pharmaceuticals Holdings is headquartered at 19925 Stevens Creek Boulevard, Cupertino, CA.

  • How can i contact Reviva Pharmaceuticals Holdings?

    Reviva Pharmaceuticals Holdings's mailing address is 19925 Stevens Creek Boulevard, Cupertino, CA and company can be reached via phone at +40 85018881.

Reviva Pharmaceuticals Holdings company profile:

Reviva Pharmaceuticals Holdings, Inc.

revivapharma.com
Exchange:

NASDAQ

Full time employees:

15

Industry:

Biotechnology

Sector:

Healthcare

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention–deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.

19925 Stevens Creek Boulevard
Cupertino, CA 95014

CIK: 0001742927
ISIN: US76152G1004
CUSIP: 76152G100